| Identification | Back Directory | [Name]
Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-3-fluoro-, 6-[(1S)-1-[[[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]oxy]carbonyl]oxy]ethyl] ester, (1S,2S,3S,5R,6S)- | [CAS]
1501974-69-1 | [Synonyms]
MGS0274
Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-3-fluoro-, 6-[(1S)-1-[[[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]oxy]carbonyl]oxy]ethyl] ester, (1S,2S,3S,5R,6S)- | [Molecular Formula]
C21H32FNO7 | [MOL File]
1501974-69-1.mol | [Molecular Weight]
429.48 |
| Hazard Information | Back Directory | [Description]
MGS0274 besylate is a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. | [Uses]
MGS0274, an ester-based lipophilic proagent of a metabotropic glutamate (mGlu)2 and mGlu3 receptor agonist MGS0008, shows improved oral bioavailability. MGS0274 has the potential for the research of schizophrenia[1][2]. | [IC 50]
mGluR2; mGluR3 | [References]
[1] Urabe H, et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability [published online ahead of print, 2020 Jul 5]. Eur J Med Chem. 2020;203:112521. DOI:10.1016/j.ejmech.2020.112521
[2] Kinoshita K, et al. Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia. Pharmacol Res Perspect. 2019;7(5):e00520. Published 2019 Sep 13. DOI:10.1002/prp2.520 |
|
|